WASHINGTON.-Biopharmaceutical Gilead Sciences said Friday that remdesivir, its treatment for the coronavirus, reduces the risk of critically ill patients by dying from the disease by up to 62% and said the drug is associated with a significant “clinical recovery improved. “
The results have been presented at the Covid-19 Virtual Conference, which in turn is part of the 23rd International AIDS Conference, according to the company in a statement.
We are working to expand our understanding of the full utility of remdesivir. To address the pandemic’s urgency, we are sharing data with the research community as quickly as possible with the goal of providing transparent and timely updates on new developments with remdesivir, “Gilead medical director Merdad Parsey said in the note.
He added that the study data sheds further light on the use of remdesivir in specific patient populations, including those who may be susceptible to higher rates of Covid-19 infection, as well as others who are particularly vulnerable, such as children or pregnant women. and postpartum.
The study took data from 312 patients in phase 3 of the study and compared them to 818 patients with similar characteristics regarding disease severity who received standard care during the same time period.
The results show that 7.6% of the patients treated with remdesivir died compared to 12.5% of the patients who received the usual care in this type of patient.
Additionally, 74.4% of patients who received Gilead drug treatment recovered on day 14, compared to 59% of patients who received standard care alone.
Likewise, Gilead Sciences highlighted that the results of an expansion of the study commissioning 5 thousand 600 additional patients that include patients with mechanical ventilation are still pending publication.
In late April, the US National Institute of Allergy and Infectious Diseases (NIAID) released preliminary results from its own study with remdesivir which showed that patients who took this drug generally recovered after 11 days, four days faster than those who did not take the drug, although the study found no statistically significant reduction in the risk of death.
The NIAID findings prompted the Food and Drug Administration (FDA) to issue an emergency use authorization for remdesivir that allowed doctors to use the drug in hospitalized patients with the virus.